Artwork

Innehåll tillhandahållet av VJOncology. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av VJOncology eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Highlights in colorectal cancer at ASCO and ESMO GI 2024

9:42
 
Dela
 

Manage episode 427338313 series 2424442
Innehåll tillhandahållet av VJOncology. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av VJOncology eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

In this week’s podcast, we will discuss the most recent developments in colorectal cancer from the 2024 ASCO and ESMO Gastrointestinal (GI) Annual Meetings held in Chicago, IL and Munich, Germany respectively. Join us as five renowned experts discuss highly anticipated findings from clinical trials across different colorectal cancer subtypes.

Heinz-Josef Lenz from the University of Southern California first comments on the expanded efficacy analysis from the Phase III CheckMate 8HW study in MSI-H/dMMR metastatic colorectal cancer and Sara Lonardi from the Veneto Institute of Oncology in Padua, Italy, discusses the health-related quality of life outcomes from the trial. John Strickler from Duke University then provides 32 month follow-up data from the MOUNTAINEER trial of tucatinib and trastuzumab in HER2+ colorectal cancer. Additionally, listen to insightful perspectives from Major Lee, The University of Pennsylvania, and David Tougeron, Poitiers University Hospital, on practice changing trials in colorectal cancer.

The post Highlights in colorectal cancer at ASCO and ESMO GI 2024 appeared first on VJOncology.

  continue reading

176 episoder

Artwork
iconDela
 
Manage episode 427338313 series 2424442
Innehåll tillhandahållet av VJOncology. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av VJOncology eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

In this week’s podcast, we will discuss the most recent developments in colorectal cancer from the 2024 ASCO and ESMO Gastrointestinal (GI) Annual Meetings held in Chicago, IL and Munich, Germany respectively. Join us as five renowned experts discuss highly anticipated findings from clinical trials across different colorectal cancer subtypes.

Heinz-Josef Lenz from the University of Southern California first comments on the expanded efficacy analysis from the Phase III CheckMate 8HW study in MSI-H/dMMR metastatic colorectal cancer and Sara Lonardi from the Veneto Institute of Oncology in Padua, Italy, discusses the health-related quality of life outcomes from the trial. John Strickler from Duke University then provides 32 month follow-up data from the MOUNTAINEER trial of tucatinib and trastuzumab in HER2+ colorectal cancer. Additionally, listen to insightful perspectives from Major Lee, The University of Pennsylvania, and David Tougeron, Poitiers University Hospital, on practice changing trials in colorectal cancer.

The post Highlights in colorectal cancer at ASCO and ESMO GI 2024 appeared first on VJOncology.

  continue reading

176 episoder

Все серии

×
 
Loading …

Välkommen till Player FM

Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.

 

Snabbguide